Clinical trial
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
NCT00337090 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00337090 |
|---|---|
| Title | A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) |
| Official title | A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Europe B.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | YM178 |
| Enrollment | 1,108 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jun 15, 2006 |
| Last update posted | Jul 2, 2013 |
| Countries | Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Russia and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: